Hutchmed begins phase one study for potential cancer treatment Read More
Hutchmed completes patient enrolment for cancer drug study Read More
Two Hutchmed drugs included on China's state approved medicines list Read More
Hutchmed China shares rise on Orphathys and Tagrisso Phase 3 study Read More
TOP NEWS: Astra transfers drug rights to Covis in USD270 million deal Read More
IN BRIEF: Hutchmed begins phase 3 trial of thrombocytopenia drug Read More
Hutchmed China sells joint venture stake for USD169 million Read More
Hutchmed starts drug combination trial for neuroendocrine tumours Read More
Hutchmed starts Japan trial for surufatinib in neuroendocrine tumors Read More
Hutchmed China's amdizalisib secures breakthrough therapy designation Read More
Hutchmed, Astra launch drug combination trial to treat lung cancer Read More
Hutchmed China to trade in Shanghai and Shenzhen through link scheme Read More
Hutchmed launches trial into drug combination to treat breast cancer Read More
Hutchmed to partner with Epizyme on tumour-targetting treatment Read More
Hutchmed research costs deepen loss; expects US launches in 2022, 2023 Read More
IN BRIEF: Hutchmed and AstraZeneca launch phase two cancer med trial Read More
AIM WINNERS & LOSERS: Hutchmed notes phase 2 trial; Tricorn drops 25% Read More
UK earnings, trading statements calendar - next 7 days Read More
AIM WINNERS & LOSERS: Pantheon up on resource upgrade, farmout talks Read More
IN BRIEF: Hutchmed tumor drug qualifies for formal review by EU agency Read More
